Patients with GPP had high treatment persistence on ixekizumab, with significant PASI score improvements. Ixekizumab maintained a favorable safety and efficacy profile across psoriasis subtypes, ...

They also had to use multiple imputation as around 70% or fewer of the new-user cohort had PASI scores available at 12 months -- a figure falling under 50% for the switcher analysis.

Interleukin-23 inhibitors, prior treatment history, and Psoriasis Area and Severity Index scores may be predictive of time to disease relapse among patients with psoriasis who achieved clinical ...

Spearman correlations between the PASI score and host genes were separately estimated for lesional and non-lesional groups. This revealed functions related to antiviral response in both groups.

Innovent’s phase 3 study of picankibart to treat moderate to severe plaque psoriasis meets all primary and key secondary endpoints ...

Johnson & Johnson’s investigational, oral interleukin (IL)-23–receptor antagonist peptide JNJ-2113 produced promising efficacy compared with placebo in patients with moderate-to-severe plaque ...

Orismilast, a phosphodiesterase 4 inhibitor, exhibited efficacy in psoriasis patients at 20 mg, 30 mg and 40 mg doses. Patients had statistically significant improvements in PASI and IGA scores.

The study's primary endpoint, the difference in the proportion of patients who achieved an outcome of a 50% improvement from baseline in Psoriasis Area and Severity Index (PASI) score (a PASI-50 ...

Previous work by the current study group noted PASI score improvements in patients treated with herring roe oil (HRO) at 26 and 65 weeks following regular diet supplementation.

PASI score is a measure of the level of severity. It stands for Psoriasis Area Severity Index. It looks at 3 dimensions, erythema, induration, and scaling or discrimination.

Patients whose PASI scores did not improve at least 75% from baseline (PASI 75) after 12 weeks of brodalumab discontinued treatment and left the study, while those who maintained PASI 75 were ...